CBIO
Crescent Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.88
+2.35%Margins
Gross margin
100.0%
EBITDA margin
-1371.0%
EBIT margin
-1417.7%
Net margin
-1371.5%
FCF margin
-1292.8%
-99.8%
Return on equity
-89.2%
Return on assets
-102.3%
Return on invested capital
0.06x
Asset turnover
-$72.7M
Cash from operations
$4.62
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026